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Activation of PPARg by synthetic ligands, thiazolidinediones, inhibits the proliferation of cancer cells. In this
report, focusing our attention on ciglitazone, we show that ciglitazone inhibits melanoma growth by inducing
apoptosis and cell-cycle arrest, whereas normal melanocytes are resistant to ciglitazone. In melanoma cells,
ciglitazone-induced apoptosis is associated with caspase activations and a loss of mitochondrial membrane
potential. Induction of cell-cycle arrest by ciglitazone is associated with changes in expression of key cell-cycle
regulators such as p21, cyclin D1, and pRB hypophosphorylation. Cell-cycle arrest occurs at low ciglitazone
concentrations and through a PPARg-dependent pathway, whereas the induction of apoptosis is caused by
higher ciglitazone concentrations and independently of PPARg. These results allow an effective molecular
dissociation between proapoptotic effects and growth inhibition evoked by ciglitazone in melanoma cells.
Finally, we show that in vivo treatment of nude mice by ciglitazone dramatically inhibits human melanoma
xenograft development. The data presented suggest that ciglitazone might be a better candidate for clinical
trials in melanoma treatment than the thiazolidinediones currently used in the treatment of type 2 diabetes,
such as rosiglitazone, which is devoid of a proapoptotic PPARg-independent function.
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INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are a
subfamily of nuclear hormone receptors. Three distinct
PPARs are termed a, d (also called b, NUC-1 or FAAR), and
g. These isoforms are encoded by separate genes and show a
distinct tissue distribution pattern. Activated PPARs hetero-
dimerize with another nuclear receptor, the retinoid X
receptor, and modulate the transcription of numerous target
genes after binding to specific PPAR response elements
(Desvergne and Wahli, 1999; Rocchi and Auwerx, 1999;
Koutnikova and Auwerx, 2002).
The transcriptional activity of PPARg is controlled by the
binding of endogenous ligands, such as prostaglandin J2
derivates, or synthetic ligands, such as thiazolidinediones
(TZDs). Among different TZDs, we found essentially four mole-
cules: rosiglitazone and pioglitazone (which are currently
used in the treatment of type 2 diabetes), troglitazone, and
ciglitazone (Schoonjans and Auwerx, 2000). This transcrip-
tion factor is important in the control of glucose and lipid
homeostasis by modulating the transcription of key genes
involved in these processes (Desvergne and Wahli, 1999;
Rocchi and Auwerx, 1999). More recently, it has been shown
that PPARg is also important in the control of programmed
cell death (apoptosis), proliferation, and differentiation.
Indeed, activation of this transcription factor by TZDs could
inhibit proliferation and induce apoptosis or differentiation of
numerous cancer cell lines isolated from colon cancer,
prostate carcinomas, gastric cancer, hepatomas, neuroblas-
tomas, and lung cancer (Kubota et al., 1998; Sarraf et al.,
1998; Chang and Szabo, 2000; Hisatake et al., 2000; Rohn
et al., 2001; Toyoda et al., 2002; Grommes et al., 2004).
Clinical studies in patients with different cancer types have
been performed or are currently in progress to show the
antineoplastic effectiveness of these ligands in vivo (Tontonoz
et al., 1997; Mueller et al., 2000; Burstein et al., 2003;
Grommes et al., 2004).
Cutaneous melanoma deriving from the transformation of
pigments producing melanocytes is one of the most lethal
cancers among young adults. Melanoma progression is
characterized by an initial radial growth phase. This phase,
is followed by the development of vertical growth phase
which has been postulated to be the first point at which the
tumor gains metastatic ability. Indeed, melanoma has a high
capability of invasion and rapid metastasis to other
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organs. The prognosis of metastatic melanoma is extremely
negative, as the various protocols of chemotherapy or
immunotherapy have not shown, for the moment, real
survival benefit (Demierre, 2006). In addition to active
prevention and early detection of melanomas, it appears
necessary to develop new approaches enabling the discovery
of new molecular target candidates for specific biotherapy
treatment of this disease.
To this end, several studies have reported that
the activation of PPARg by specific ligands might be used
to inhibit melanoma development (Placha et al., 2003;
Freudlsperger et al., 2006; Liu et al., 2006). Most of these
studies showed that ciglitazone is the most efficient
TZD for inhibiting melanoma cell growth, whereas Nunez
et al. (2006) have shown that ciglitazone at high doses (50 mM)
is inactive on melanoma cells. These effects of PPARg
ligands have been ascribed to the proapoptotic action
of high TZD concentration (Placha et al., 2003; Liu et al.,
2006), but Mossner et al. (2002) found that PPARg
ligands could inhibit cell proliferation by a mechanism
independent of apoptosis. Thus, data reported in the
above studies are controversial and it is rather difficult to
draw a clear picture of the effect of PPARg ligands on
melanoma tumorigenicity. Thus, it was important to further
investigate the molecular mechanisms by which PPARg
ligands affect melanoma growth and to demonstrate their
efficiency in vivo.
In the present report, we dissected the molecular pathways
involved in the effect of PPARg ligands on melanoma cells.
We focused our attention on ciglitazone, the most efficient
PPARg ligand in terms of melanoma growth inhibition. We
demonstrate that ciglitazone inhibits melanoma cell growth
by inducing cell-cycle arrest and apoptosis. Cell-cycle arrest
occurs at low ciglitazone concentration and through a
PPARg-dependent pathway, whereas apoptosis induction is
caused by higher ciglitazone concentration and indepen-
dently of PPARg transcriptional activation. Interestingly, in
contrast to melanoma cells, normal human melanocytes
(NHMs) are resistant to ciglitazone-induced cell death.
Finally, to our knowledge it has not previously been reported
that treatment of nude mice by ciglitazone dramatically
impairs the growth of melanoma tumor xenografts. Taken
together, our data identify ciglitazone as a new anti-
melanoma drug and might provide the initial impetus for
clinical trials using ciglitazone in melanoma treatment.
RESULTS
Effect of TZDs on A375 melanoma viability and PPARc activity
First, we wished to compare the effect of several TZDs on
melanoma cell viability and on PPARg activation. Analysis of
cell survival using an XTT assay showed that treatment of
A375 melanoma cells with ciglitazone for 24 hours led to a
dose-dependent decrease in cell viability (Figure 1a).
Ciglitazone decreased cell viability by about 30% at 1 mM.
At concentrations of 10mM of ciglitazone and compared to
DMSO-treated cells, only 40% of cells were viable. This
result was comparable to that obtained with the proapoptotic
effector, straurosporine. Other PPARg ligands, such as
pioglitazone and rosiglitazone, had a weak effect on viability,
with only 30 and 15% inhibition, respectively, at 10 mM
concentration. Finally, troglitazone showed no effect on cell
viability at 1 mM but induced a marked decrease of cell
viability at 10 mM, comparable to that observed with
ciglitazone.
We next studied the effect of these PPARg ligands on
PPARg transcriptional activity using the pGL3-(Jwt)3TKLuc
reporter construct (Figure 1b). Ciglitazone and pioglitazone
showed dose-dependent activation of PPARg. This activation
reached a maximum at 10 mM of PPARg ligands. Concerning
rosiglitazone and troglitazone, maximal PPARg activation
was found at a lower concentration (0.1 and 1 mM,
respectively). This high PPARg transcriptional activity in-
duced by pioglitazone, rosiglitazone, and troglitazone at 1 mM
did not result in a meaningful inhibition of melanoma
viability. No clear correlation between the ability of PPARg
ligands to activate PPARg and their ability to inhibit cell
viability can be observed, indicating that the activation of
PPARg is not sufficient to inhibit melanoma cell viability.
Because ciglitazone was the most efficient PPARg ligand
in the inhibition of melanoma cell viability, we further
analyzed the effect of this TZD.
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Figure 1. Effect of TZDs on A375 melanoma viability and PPARc activity. (a)
Cells were treated with different concentrations of a TZD for 24 hours, and
cell viability was measured by XTT staining. XTT activities are expressed in
percent of control (100%). Data are mean±SD of three independent
experiments performed in triplicate. (b) A375 melanoma cells were
transfected with pGL3-(Jwt)3TKLuc reporter construct. After 24 hours, cells
were treated with different concentrations of TZD. Measurement of luciferase
activity was carried out 24 hours after treatment. Variability of transfection
was normalized with bGal activity and results were expressed in percent of
control (100%). Data are mean±SD of three independent experiments
performed in triplicate. *Po0.05; **Po0.01; ***Po0.001.
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A low dose of ciglitazone induces a G0/G1 cell-cycle arrest of
A375 melanoma cells
First, we determined if melanoma cells underwent a
modification of their cell cycle in response to ciglitazone.
Flow cytometry analysis showed that cells treated with
DMSO presented a cycle characteristic of cells in the
exponential growth phase (Figure 2a). Indeed, 65% of the
cells were in G0/G1 phase, 21% were in S phase, and almost
none were detected from the sub-G1 population. In response
to 0.1 and 1 mM ciglitazone, we observed an increase in the
percentage of cells in G0/G1 phase, which reached 73 and
78%, respectively, as well as a reduction in the percentage of
cells in S phase (14 and 7%, respectively). These results
suggest an increase of cell-cycle duration in response to low
concentrations of ciglitazone. A total of 38% of cells treated
with 10 mM ciglitazone were detected in the sub-G1 popula-
tion, suggesting an induction of cell death.
We next analyzed by western blot the expression of
proteins involved in cell-cycle regulation (Figure 2b). In
response to ciglitazone we observed a decrease in the
expression of cyclin D1, which is important in G1/S
transition. In contrast, ciglitazone induced an increase in
the expression of the cyclin-dependent kinase inhibitor
p21Cip1/Waf1. Moreover, the hyperphosphorylation of
pRb, a key protein that permits G1/S transition, is markedly
reduced following exposure to ciglitazone. Interestingly, we
observed that stimulation with 10 mM ciglitazone led to the
disappearance of these three proteins.
Taken together, these results suggest that ciglitazone-
induced cell-cycle arrest can be attributed to changes in the
expression and activity of key cell-cycle regulators.
A high dose of ciglitazone induces apoptosis in A375 melanoma
cells
As shown in Figure 3a, cells treated with 10 mM ciglitazone
not only detached from the substratum but also formed
membrane blebs that are characteristic of apoptotic cells
(Coleman et al., 2001). This hypothesis was tested by
studying the effect of ciglitazone on key molecular markers
of apoptosis. We were first interested in the expression of
caspases 3 and 9, two key enzymes involved in apoptotic
processes (Figure 3b). Concerning caspase 9, which is the
initiating caspase of apoptosis through the mitochondrial
intrinsic pathway, we observed that 10 mM ciglitazone
induced a strong reduction in its zymogenic form that was
characteristic of its activation. We obtained the same profile
of reduction with the zymogenic form of caspase 3. After
activation, this caspase is able to cleave many cellular
substrates. One of the best described is the DNA repair
enzyme poly(ADP-ribose) polymerase (PARP), and stimula-
tion of cells with 10 mM ciglitazone led to a cleavage of PARP.
As expected, the treatment of cells with a specific pan-
caspase inhibitor ZVAD-fmk abolished the effect of ciglita-
zone on caspases proteolytic processing and cleavage of
PARP.
The disappearance of the zymogenic form of caspases
does not necessary result in their activation. Therefore, we
carried out caspase activation assays. As shown in Figure 3c,
caspase 3 activation was effective at 10 mM ciglitazone. Under
this condition, the activity of caspase 3 was 21 times higher
than the activity observed in cells treated with DMSO
(control conditions). Incubation of A375 cells with 1 mM of
staurosporine was used as a positive control of caspase
activation. Concerning caspase 9, we observed that ciglita-
zone-induced activation is dose dependent. Indeed, whereas
we did not observe any activation of caspase 9 in response to
ciglitazone 0.1 mM, its activation increased 2.5-fold when the
cells were treated with 1 mM ciglitazone and 7-fold in
response to 10 mM ciglitazone. These results show that
ciglitazone significantly increases the activities of caspases
3 and 9.
During apoptosis, the mitochondrial outer membrane
becomes permeable, leading to the loss of mitochondrial
membrane potential (DCm). In line with this, Figure 3d shows
that ciglitazone is able to induce the loss of the membrane
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Figure 2. Effect of ciglitazone on cell-cycle progression in A375 melanoma
cells. (a) Cells treated for 24 hours with ciglitazone were detached and their
DNA contents were measured by flow cytometry. The table displays the
percentage of cells in G0/G1 (M1: non cycling cells), S (M2: DNA replication)
and sub-G1 stages (M4: apoptotic cells). One representative experiment of
three is shown. (b) A375 melanoma cells were treated for 24 hours with
increasing concentrations of ciglitazone. Cell lysates (20 mg total protein per
lane) were separated by 12% SDS–PAGE and analyzed by western blot using
the indicated antibody. ERK2 was used as a loading control. One
representative experiment of three is shown.
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potential. As expected, the uncoupler carbonyl cyanide
p-(trifluoromethoxy) phenylhydrazone (FCCP) caused a com-
plete dissipation of DCm.
Taken together, our results indicate that high ciglitazone
concentration (10 mM) triggers apoptosis by acting at least in
part at the mitochondrial level.
The effect of ciglitazone on viability in melanoma cell lines is
not correlated with the PPARc protein level
Next we compared the sensitivity of NHMs and different
melanoma cell lines to ciglitazone. XTT assays showed that
ciglitazone, up to 10 mM, had no effect on normal melanocyte
number (Figure 4a). In contrast, ciglitazone decreased by
40% the viability of WM35 cells at 10 mM, and by 30 and 60%
the viability of A375 and 501 mel cells at 1 and 10 mM,
respectively.
Cell counting using Trypan blue (Figure 4b) showed
that increased concentrations of ciglitazone strongly
decreased proliferation of WM35, A375, and 501 mel cells
after 60 hours of treatment. For example, ciglitazone (1 mM)
decreased by 40% the number A375 and 501 mel cells. At
10 mM of ciglitazone, the cell number of the three melanoma
cells represented only 15% of the total cell number found in
control conditions. These data suggest that ciglitazone-
induced cell growth inhibition is not restricted to a particular
melanoma cell line.
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Figure 3. Ciglitazone induces apoptosis in A375 melanoma cells. (a) A375 melanoma cells treated with ciglitazone demonstrated a characteristic apoptotic cell
morphology. Scale bar¼ 20 mm. DIC pictures of cells treated for 24 hours with DMSO (left panel) or ciglitazone 10 mM (right panel). (b) After 24 hours of
treatment with the ciglitazone in the presence or absence of ZVAD-fmk, cell lysates (20 mg total protein per lane) were separated by 10% SDS–PAGE and
analyzed by western blot using the indicated antibody. ERK2 was used as a loading control. One representative experiment of three is shown. (c) After 24 hours
of treatment with ciglitazone, cells were lysed and caspase 3 or 9 activity, respectively, was monitored by measuring cleavage of Ac-DEVD-AMC or AC-LEHD-
AMC-specific caspase substrate in the presence of 30mg of cell lysate. Lysate from cells treated for 5 hours with 1mM staurosporine are used as a positive control
of caspase activation. Results are expressed in relative fluorescence units per minute and per milligram of protein (UAFmin1mg1 of prot.). Data are mean±SD
of three independent experiments performed in triplicate. (d) Mitochondrial membrane potential (DCm) was measured by loss of MitoTracker Red fluorescence.
A375 cells treated for 24 hours with ciglitazone were incubated for 30minutes at 37 1C with MitoTracker Red 580. MitoTracker probe a passively diffuses across
the plasma membrane and accumulates in active mitochondria. Cells pretreated with FCCP, an uncoupling agent of mitochondria, are used as a negative
control. The percentage of cells that have lost their fluorescence, is indicated in the figure.
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Contrary to its effect on melanoma cells, 1 and 10 mM of
ciglitazone had no effect on the viability of normal
melanocytes. As expected, a significant decrease in NHM
number and viability was observed after treatment with
staurosporin (data not shown).
The resistance of NHM to ciglitazone might be due to a
lack of PPARg expression. To test this, we performed western
blotting analysis of PPARg expression levels in NHM and in
different melanoma cell lines (Figure 4c). PPARg protein was
expressed at different levels in NHM and tested cell lines.
Indeed, PPARg expression was very weak in NHM and in
WM35 cells; its expression was much stronger in 501 mel
and A375 melanoma cell lines. Ciglitazone is able to induce
apoptosis in melanoma cells expressing very low level of
PPARg, suggesting that ciglitazone might act independently
of PPARg.
100
80
60
40
20
0
XT
T 
ac
tiv
ity
 (%
)
DM
SO 0.1 1 10
DM
SO 0.1 1 10
DM
SO 0.1 1 10
DM
SO 0.1 1 10
Ciglitazone (μM) Ciglitazone (μM) Ciglitazone (μM) Ciglitazone (μM)
NHM
WM35
A375
501 mel
NHM
WM35
A375
501 mel
***
**
**
******
*
120
100
80
60
40
20
0
Ce
ll n
u
m
be
r (
%)
PPARγ
ERK2
NHM WM35 501 mel A375
55 kDa
42 kDa
***
***
***
*
*
DM
SO 0.1 1 10
DM
SO 0.1 1 10
DM
SO 0.1 1 10
DM
SO 0.1 1 10
Ciglitazone (μM) Ciglitazone (μM) Ciglitazone (μM) Ciglitazone (μM)
Figure 4. Ciglitazone effects on cell proliferation in normal human melanocytes (NHMs) and in melanoma cells. (a) Cells were treated with different
concentrations of ciglitazone over 24 hours and cell viability was measured by XTT staining. XTT activity was expressed as percentage of control (100%). Data
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PPARc silencing does not affect ciglitazone-induced apoptosis
To evaluate the function of PPARg receptors in the effects of
ciglitazone, we silenced PPARg with two specific siRNAs.
Figure 5a shows the effective depletion of PPARg by two
different siRNA against PPARg. As shown in Figure 5b,
inhibition of PPARg significantly prevented cell growth
inhibition induced by 1 mM ciglitazone, indicating that at this
concentration ciglitazone induces diminution of cell viability
through the PPARg receptor. In contrast, at 10 mM ciglitazone,
knocking-down PPARg with siRNA did not prevent cell
death, suggesting a PPARg-independent mechanism. Similar
results were obtained using cell counting assays (Figure 5c).
Ciglitazone inhibits melanoma tumor xenograft development in
mice
Finally, to determine the antineoplastic effect of ciglitazone
in vivo, A375 melanoma cells (2.5 106) were injected
subcutaneously in 6-week-old female athymic nude mice and
treated 7 days after cell injection by vehicle or ciglitazone
(50mg kg1 day1) over a period of 2 weeks.
Untreated control mice rapidly developed visible tumors
and dramatic growth was observed throughout the course of
the study (Figure 6a). In contrast, treatment of mice with
ciglitazone markedly attenuated the ability of cells to develop
visible tumors. Indeed, three of seven ciglitazone-treated
mice had no measurable tumors. Moreover, visible tumors
were significantly smaller and weighed less than tumors from
untreated control mice (Figure 6b). These data clearly
demonstrate that ciglitazone has anti-melanoma activity
in vivo.
To determine the molecular mechanisms involved in the
antineoplastic effects of ciglitazone in vivo, activation of
caspase 3 was studied by immunofluorescent staining on
tumor sections from mice treated for 2 weeks with vehicle or
ciglitazone 50mg kg1 day1 (Figure 6c). Sections of tumors
from mice treated with ciglitazone show a dramatic increase
in staining to active caspase 3 compared to sections of tumors
from control mice injected with vehicle. Thus, the reduction
of tumor volume and weight observed in ciglitazone-treated
mice seems to be, at least in part, related to the induction of
apoptosis.
DISCUSSION
The TZDs are a family of antidiabetic drugs used in the
treatment of non-insulin-dependent type 2 diabetes. Their
actions are largely mediated through binding to PPARg and the
activation of this ligand-activated nuclear transcription factor.
TZDs increase insulin sensitivity, decrease hepatic neogluco-
genesis, and favor adipocyte differentiation, limiting thereby
their growth potential. This latter observation has prompted
numerous studies on the role of TZDs in the regulation of tumor
cell proliferation and apoptosis. Encouraging results emerged
from these studies indicating that TZDs can potentially be used
as efficient anticancer drugs in various neoplasms such as
prostate carcinomas, colon, and lung cancers (Grommes et al.,
2004; Lehrke and Lazar, 2005). In the present study, using
in vitro and in vivo approaches, we demonstrate the potent
anti-melanoma activity of ciglitazone.
Initially, we compared the ability of different TZDs to
induce growth inhibition of melanoma cell lines and to
activate PPARg. Both ciglitazone and troglitazone are able to
inhibit the viability of A375 cells in a dose-dependent
manner. Interestingly, compared to ciglitazone and troglita-
zone, pioglitazone and rosiglitazone have a weaker effect on
the viability of the metastatic melanoma A375 cell line,
although their ability to activate PPARg is the same
(pioglitazone) or better (rosiglitazone) than that of the two
other ligands. It has been previously shown that different
PPARγ
ERK2
Si 
CT
L
Si 
PP
AR
γ 1
Si 
PP
AR
γ 2
120
100
80
60
40
20
0
120
100
80
60
40
20
0
XT
T 
ac
tiv
ity
 (%
)
DMSO 0.1 1 10
Ciglitazone (μM)
Si CTL
Si PPARγ 1
Si PPARγ 2
Si CTL
Si PPARγ 1
Si PPARγ 2
**
**
Ce
ll n
u
m
be
r (
%)
DMSO 0.1 1 10
Ciglitazone (μM)
Figure 5. Effect of PPARc depletion on ciglitazone-induced cell growth
inhibition. Cells transfected by siRNA CTL or by two different siRNA PPARg
were treated with different concentrations of ciglitazone over 24 hours. (a)
PPARg expression was analyzed by western blotting. ERK2 was used as a
loading control. (b) Transfected cells were treated with different
concentrations of ciglitazone over 24 hours. Cell viability was measured by
XTT staining. XTT activity is expressed in percent of control (100%). Data are
mean±SD of three independent experiments performed in triplicate.
**Po0.01. (c) Transfected cells were treated with different concentrations of
ciglitazone over 60 hours before being counted using Trypan blue. Cell
numbers are expressed in percent of control (100%). Data are mean±SD of
three independent experiments performed in triplicate. **Po0.01.
www.jidonline.org 1213
T Botton et al.
Ciglitazone Inhibits Melanoma Growth
PPARg ligands did not induce a similar pattern of cofactor
recruitment, and such a differential cofactor recruitment
could result in different biological effects (Rocchi et al.,
2001). Therefore, it is tempting to speculate that ciglitazone
and troglitazone recruit specific cofactors that are important
in modulating the PPARg target genes involved in prolifera-
tion arrest and/or cell death. To better understand the
discrepancy between the effects of TZDs on PPARg activation
and melanoma cell viability, we further analyzed the effects
of ciglitazone on A375 melanoma cells.
Low doses of ciglitazone induce a G0/G1 arrest, which is
associated at the molecular level with a dramatic reduction of
cyclin D1 expression, a marked increase in the expression of
cyclin-dependent kinase inhibitor p21Cip1/Waf1, and hypo-
phosphorylation of pRb. Cyclin D1 is one of the cyclins that
may affect the G1 phase of the cell cycle in different tumors
(Sherr and Roberts, 2004). Previous studies carried out in
other cell models have reported that PPARg agonists may
downregulate cyclin D1 expression both by inhibiting its
transcription (Wang et al., 2001) and inducing proteasome-
dependent degradation of the protein (Qin et al., 2003). In
addition, TZDs have already been reported to influence
cyclin-dependent kinase inhibitors. For example, troglitazone
induced upregulation of p21Cip1/Waf1 in thyroid and
pancreatic cancer cells (Chung et al., 2002; Kawa et al.,
2002), whereas ciglitazone did not upregulate p21Cip1/Waf1
in thyroid cancer cells (Martelli et al., 2002). Thus, the effect
of PPARg ligands on cyclin-dependent kinase inhibitors
seemingly depends on tumor cell types. Finally, in agreement
with our results in a melanoma system, several studies
performed in other cancer cell lines described a decrease in
phosphorylation of pRb after TZD treatment (Kawa et al.,
2002; Strakova et al., 2004; Aiello et al., 2006), indicating
that PPARg ligands could also modify pRb activation in
different cancer cell lines.
High doses of ciglitazone induce the cell rounding, sub-G1
cell accumulation, caspase-3/9 activation, and PARP clea-
vage that are the hallmarks of apoptosis. These findings are in
agreement with previous results demonstrating a predomi-
nant apoptotic effect of PPARg agonists in different cancer
cells (Grommes et al., 2004). However, a report of Nunez
et al. (2006) showed that A375 melanoma cells are
completely resistant to ciglitazone up to 50mM. This
discrepancy could be explained by the different culture
medium and different technical approaches used. Treatment
of cells with ciglitazone decreases mitochondrial potential,
demonstrating that ciglitazone-induced apoptosis is mediated
at least in part through the mitochondrial pathway. Of note,
the decrease in pRb, cyclin D1 and p21 expression observed
at 10 mM of ciglitazone can be explained by the degradation
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Figure 6. Effect of ciglitazone on melanoma tumor growth in mice. Mice were inoculated subcutaneously with A375 melanoma cells (2.5 106), and after 7
days animals (n¼6 in each group) were treated with ciglitazone (50mgkg1 day1) or labrafil over 16 days. (a) The growth tumor curves were determined
by measuring the tumor volume. (b) Mice were killed and tumors were weighed. *Po0.05; **Po0.01. (c) Frozen sections of tumors from mice treated with
labrafil (left) or 50mgkg1 day1 ciglitazone (right) were fixed and stained for active caspase 3 (green) and DAPI (blue). Lower panels show merge of active
caspase 3 and DAPI staining. FITC-conjugated anti-rabbit secondary antibodies were used. DAPI staining was used to identify the cell nucleus. Slides were
examined with a Zeiss Axiophot fluorescence microscope. Representative sections are shown. The experiment was repeated on sections from six mice per
condition. Scale bar¼150 mm.
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of these three proteins that were reported to be a substrate of
caspase 3 (Katsuda et al., 2002; Woo et al., 2003). Several
studies performed in other cancer cell lines have shown that
synthetic ligands of PPARg could modify the expression of the
proapoptotic protein, Bax (Avis et al., 2001; Zander et al.,
2002; Grommes et al., 2004; Yang et al., 2005; Akasaki et al.,
2006). Under our conditions, Bax expression in A375
melanoma cells is not modified by ciglitazone (data not
shown). These results are in agreement with previous studies
showing that ciglitazone treatment of human liver cancer cell
lines and human thyroid carcinoma cells did not affect Bax
level (Ohta et al., 2001; Toyoda et al., 2002).
Interestingly, no significant apoptosis is induced by 0.1 or
1 mM ciglitazone in A375 cells, whereas 10 mM ciglitazone
significantly increases caspase activation and PARP cleavage.
Cell-cycle arrest occurs at ciglitazone concentrations lower
than those required to induce apoptosis. These observations
suggest that cell-cycle regulation and apoptosis induced by
ciglitazone in A375 melanoma cells are independent
phenomena, probably mediated by different mechanisms.
Ciglitazone induces the inhibition of cell growth and
viability of other melanoma cell lines such as WM35 and 501
mel. In contrast, ciglitazone, as well as the other TZDs tested
(not shown), are not efficient in affecting the growth and
viability of normal melanocytes. Indeed, patients with type 2
diabetes treated with a TZD do not show any alteration in
skin pigmentation, suggesting that these drugs do not alter
normal melanocyte functions (Schoonjans and Auwerx,
2000). Further, 1 mM ciglitazone inhibits growth in melanoma
cells expressing high levels of PPARg (501 mel, A375), but
has very little effect in WM35 cells expressing low levels of
PPARg. By contrast, at 10 mM ciglitazone inhibits viability
with a similar efficiency in these three cell lines.
These observations, together with the lack of correlation
between PPARg activation and the inhibition of cell viability,
strongly suggest that ciglitazone acts through a PPARg-
independent pathway. To verify that ciglitazone can indeed
act independently of PPARg in melanoma cells, we silenced
PPARg using specific siRNA. The effects of low doses of
ciglitazone are completely prevented by PPARg silencing,
whereas the effect of high concentration of ciglitazone
(10 mM) is not modified by PPARg silencing. Taken together,
the data presented in this report indicate that low doses of
ciglitazone induce cell-cycle arrest through PPARg activa-
tion, whereas high doses of ciglitazone promote apoptosis
independently of PPARg. In addition, these results suggest
that the resistance of melanocytes to ciglitazone action could
not be completely explained by a weak PPARg expression in
the cell, as the effect of ciglitazone on apoptosis seems to be
PPARg independent, and WM35 cells that expressed PPARg
levels that were approximately similar to those of normal
melanocytes are sensible to high concentrations of ciglita-
zone. This indicates that ciglitazone action on cell viability is
limited to transformed cell lines and likely reflects a tumor-
specific regulation. Several recent studies, using ciglitazone
and troglitazone analogs that do not bind PPARg, have
demonstrated that the effect of PPARg ligands on cell viability
could be promoted in a PPARg-independent manner (Weng
et al., 2006). In particular, ciglitazone has been demonstrated
to induce apoptosis in prostate cancer cells in part through
inhibition of Bcl-xL/Bcl-2 functions independent of PPARg
activation (Shiau et al., 2005). In our cell system, we have not
detected modifications in the expression of Bcl-2 proteins
after ciglitazone treatment (data not shown). However, we
cannot exclude that Bcl-2 function is altered after ciglitazone
treatment in A375 cells.
Nevertheless, the mechanism by which ciglitazone
induces apoptosis independently of PPARg activation in
melanoma cells remains unclear, but could involve the
regulation of additional targets in melanoma cells. Future
studies in our lab will address the mechanism(s) through
which ciglitazone signaling induces a specific death in
melanoma cells.
Finally, we have evaluated the potential anti-melanoma
activity of ciglitazone in a mouse model of melanoma
xenografts. Importantly, our results show that the short-term
administration (14 days) of ciglitazone dramatically reduces
or abolishes the development of melanoma tumors in mice.
In addition, ciglitazone does not appear to induce toxicity, as
the body weight (data not shown) and overall appearance of
mice given a TZD are not different from those of controls.
These observations demonstrate that ciglitazone has a strong
anti-melanoma activity in vivo. To determine whether
ciglitazone is cytotoxic or cytostatic, we prepared immuno-
histological staining of mouse tumor sections. Staining
showed an increase in caspase 3 activation in the tumors of
ciglitazone-treated mice. Cyclin D1 and p21 stainings have
also been studied, but the expression of neither protein
appears to be modulated in response to ciglitazone treatment
(data not shown). These results suggest that in vivo ciglita-
zone effects are cytotoxic and correlate with the induction of
apoptosis.
In summary, ciglitazone treatment results in the inhibition
of cell proliferation and tumor growth in mice. These effects
in intact cells are likely mediated, at low ciglitazone
concentrations, by an activation of PPARg and an arrest of
cells in the G0/G1 phase. More importantly, a strong
proapoptotic effect is induced by high ciglitazone concentra-
tions independent of PPARg.
Several studies have raised the possibility of using PPARg
ligands to inhibit cancer cell growth, including some phase II
clinical trials. However, the findings in our study comple-
ment several studies in other cancer cell types (Michalik
et al., 2004), demonstrating that a major part of the
antitumoral activity of TZDs is mediated through a PPARg-
independent mechanism. Thus, it will be judicious to initiate
detailed preclinical studies with PPARg-inactive TZD analogs
to identify the molecular mechanisms involved in their
PPARg-independent effects in melanoma and to evaluate
their potential as new drugs for melanoma treatment.
MATERIALS AND METHODS
Materials
Ciglitazone, staurosporine, hydrocortisone, insulin, phorbol-12
myristate 13-acetate, MCDB 153 medium, sodium fluoride,
dimethylacetamide, Tween 80, sodium orthovanadate, 4-(2-ami-
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noethyl)-benzene-sulfonyl fluoride, aprotinin, and leupeptin were
purchased from Sigma Chem. Co. (St. Louis, MO). Labrafils M1944
Cs was purchased from Gattefosse´ (Saint Priest, France). The
protease inhibitor acetyl-DEVD-CHO was from MERCK Eurolab
(Fontenay Sous Bois, France). DMEM, penicillin/streptomycin and
trypsin were from Invitrogen (San Diego, CA), fetal calf serum from
Hyclone (Brevieres, France). Stem cell factor (SCF) was obtained
from R&D System (Lille, France). Monoclonal PPARg E8 and
monoclonal p21 were from Santa Cruz Biotechnology (Le Perray
en Yvelines, France). Monoclonal cyclin D1 and pRb were from BD
Pharmigen (Erembodegem, Belgium). The polyclonal procaspase-9
(Casp9), monoclonal procaspase-3 (Casp3) antibodies, cleaved
PARP, monoclonal ERK2 antibodies were from Cell Signaling
Technology Inc. (Beverly, MA).
Cell cultures
Human melanocyte suspensions were obtained from foreskins of
Caucasian children as previously described (Larribere et al., 2004).
Human primary melanocytes were grown in MCDB153 medium
supplemented with 2% fetal calf serum, 0.5 mgml1 hydrocortisone,
5mgml1 insulin, 16 nM phorbol-12 myristate 13-acetate, 1 ngml1
basic fibroblast growth factor, 20mgml1 bovine pituitary extract,
10 mM forskolin, and penicillin/streptomycin (100Uml1/
50mgml1). The human melanoma cell line WM35 was generously
provided by M Herlyn (Wistar Institute, Philadelphia, PA) and
maintained as described (Li et al., 2003). The human melanoma cell
line 501 mel was generously provided by C Goding (Marie Curie
Research Institute, Oxted, United Kingdom) and maintained as
described (Goodall et al., 2004). The parental human A375
melanoma cell line (CRL-1619) was purchased from American
Tissue Culture Collection (Molsheim, France) and maintained as
previously described (Robert et al., 2006). For each experiment, cells
were starved in appropriate medium without fetal calf serum for
14 hours before drug stimulation. NHM were starved in MCDB153
medium containing only penicillin/streptomycin (100Uml1/
50mgml1).
Cell viability test
Cell viability was assessed using the cell proliferation kit II (XTT;
Roche Molecular Biochemicals, Indianapolis, IN) according to the
manufacturer’s protocol. Briefly, cells (3 103 cells per well in 96
wells) were grown in triplicate in 100ml of the corresponding
medium. Cells were next treated with ciglitazone for the time and
the concentration indicated in the figure legends and then incubated
with dye. Cell viability, measured at 490 nm, is expressed as the
percentage of the value in DMSO-treated cells.
Transfections and luciferase assays
Melanoma cells were seeded in 24-well dishes, and transient
transfections were performed the following day using 2 ml Lipofecta-
mine (Gibco-BRL, Eragny, France) and 0.3 mg of total plasmid DNA
in a 200-ml final volume. pCMVbGal was cotransfected to control
the variability of transfection efficiency in the reporter assays.
At 24 hours after stimulation, cells were harvested in 50 ml of
lysis buffer and soluble extracts assayed for luciferase and
b-galactosidase activities. All transfections were repeated several
times using different plasmid preparations. Luciferase assays were
carried out exactly as described (Rocchi et al., 2001). The
pGL3-(Jwt)3TKLuc reporter construct is described elsewhere (Rocchi
et al., 2001).
Flow cytometry analysis
Cells exposed to ciglitazone or staurosporine were detached in PBS/
EDTA 1mM and stained with propidium iodide. Fluorescence was
measured by using the FL2 channels of a FACScan (Becton Dickinson,
Cowley, UK) and data analyzed with CellQuest software. Apoptotic
cells containing a DNA content o2N appear in the sub-G1 region.
To assess mitochondrial membrane potential (DCm), cells were
exposed to MitoTracker Red 580nm in a concentration of 150 nM
(Molecular Probes, Eugene, OR) for 30minutes at 37 1C. Changes in
dye fluorescence at 25 1C were analyzed in a FACScan using an
excitation of 488 nm and emission wavelength of 580 nm.
Caspase activity
Caspases activities were carried out exactly as described (Hilmi
et al., 2008b).
Western blot assays
Cells were grown in six-well dishes with or without different
effectors at the time indicated in the corresponding figure. Cells were
then lysed and western blot analysis was performed as described
(Hilmi et al., 2008a).
Small interfering RNA-mediated downregulation of PPARc
Small interfering RNAs (siRNAs) were from Santa Cruz Biotechnol-
ogy (sc-29455) and Invitrogen. As a nonspecific control, a scramble
sequence for PPARg siRNA was used. siRNA duplex was transfected
into cells using Lipofectamin RNAiMAX (Invitrogen). Transfections
were carried out in six-well plates at 50–60% confluency with a final
concentration of 20 nM of siRNA, and cells were harvested after
72 hours.
In vivo murine cancer model
Animal experiments were carried out in accordance with the
Declaration of Helsinki and were approved by a local ethical
committee. Female immune-deficient BALB/c nu/nu (nude) mice
were obtained at 6 weeks of age from Janvier Laboratory. Animals
were maintained in a temperature-controlled facility (22 1C) on a 12-
hour light/dark cycle and were given free access to food (standard
laboratory chow diet from UAR, Epinay-S/Orge, France).
Mice were inoculated subcutaneously with A375 melanoma cells
(2.5 106 cells per mouse in PBS). After 7 days, animals received an
intraperitoneal injection of ciglitazone (50mgkg1day1) dissolved in a
mixture of Labrafils M1944 Cs, dimethylacetamide, and Tween 80
(90:9:1%, vol/vol/vol) as previously described (Miot-Noirault et al.,
2004) for 16 days. The growth tumor curves were determined by
measuring the tumor volume using the equation V¼ (LW2)/2. After
24 days, mice were killed by CO2 inhalation and tumors were weighed.
Immunofluorescence detection of active caspase 3 on
melanoma biopsies
Frozen sections (5mm) of mouse tumor samples were embedded in
optimal cutting. Temperature Tissue-Tek compound were fixed in
4% paraformaldehyde in PBS for 10minutes, and stained for active
caspase 3 using a rabbit polyclonal antibody (dilution, 1:50; Cell
Signaling Technology No. 9661). Sections were also stained for
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DAPI. After washing with PBS, sections were incubated with FITC-
conjugated anti-rabbit (Molecular Probes). Slides were examined
with a Zeiss Axiophot fluorescence microscope.
Statistical analysis
Results are presented as mean±SE with experiment numbers
indicated in the figure legends. Statistical significance was assessed
using the Student’s t-test. Po0.05 was accepted as statistically
significant.
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